{
    "id": "53878496",
    "text": "Valneva SE is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva was founded in 2013 through the merger of Intercell and Vivalis SA. It has been listed on the Vienna Stock Exchange and Euronext since May 28, 2013. Marketed vaccines generated by Valneva include Ixiaro, a vaccine against Japanese encephalitis (approved in Europe, America and Australia) and Dukoral, a vaccine against cholera (approved in Europe, America and Australia) Some of its candidates have failed in clinical trials: VLA43, a therapeutic vaccine against Pseudomonas Aeruginosa, V710, a therapeutic vaccine against Staphylococcus aureus (in collaboration with Merck), and IC41, therapeutic vaccine against hepatitis C ==References== ==External links== * *Vienna Stock Exchange: Market Data Valneva SE Category:Companies based in Lyon Category:Companies based in Vienna Category:Biotechnology companies of France Category:Pharmaceutical companies established in 2013 ",
    "title": "Valneva SE"
}